CRO compensation is more variable than any other C-suite role. Two people with the same title at similar-stage companies can be $500K apart in cash and $10M apart in equity. That variance isn't random, it maps to five things: company stage, prior CRO track record, equity leverage, the CRO's ability to bring team, and whether the role is truly a CRO or an inflated VP Sales title.
This guide breaks down realistic 2026 CRO comp packages across all five dimensions, with the traps that lead to bad offer decisions on both sides of the table.
Bands below reflect US B2B SaaS. Public company data is drawn from proxy statements and comp research firms (Compensia, Radford). Coastal cities add 5-10% to base (equity component doesn't move by geography). Bands are directional, actual offers depend heavily on the CRO's track record with the specific hiring board.
The five dimensions, in order of impact
1. Company stage
Stage sets the base, and it moves more than most people expect.
| Stage | Base | OTE | Typical equity |
|---|---|---|---|
| Series A | $200K to $250K | $320K to $400K | 0.75% to 1.5% |
| Series B | $230K to $280K | $380K to $470K | 0.5% to 1.0% |
| Series C | $260K to $310K | $430K to $520K | 0.25% to 0.6% |
| Series D and later | $280K to $340K | $470K to $580K | 0.15% to 0.4% |
| Pre-IPO | $300K to $380K | $520K to $650K | 0.10% to 0.3%, usually RSUs |
| Public | $350K to $450K | $600K and up | $400K to $1.2M annual RSU grant |
Published base figures for the role cluster at $231K to $302K across all stages, which is why a single number is useless: it averages a Series A CRO and a public company CRO into a figure that describes neither.
Pay mix at C-level is typically 70/30, so OTE is roughly 1.43x base. Earlier stage often runs closer to 60/40, which raises the multiple and the risk together.
2. Prior CRO track record
The largest single variance inside a stage. A CRO who has taken a company from $10M to $50M ARR before commands materially more than a first-time CRO stepping up from VP Sales, and the gap widens with stage: at Series A a board will take a first-timer, at Series D they usually will not.
Ask what the number actually was. "Scaled revenue 3x" at a company that went from $2M to $6M is a different job from $30M to $90M.
3. Equity leverage
The dimension people underweight, and where most of the real money sits.
Equity percentages shrink as valuation rises, but dilution means the headline percentage is not what you end up with. Every round dilutes existing holders by roughly 10 to 25 percent, so 1.5 percent granted at Series A can be closer to 0.8 percent by Series C. If you are joining early, model the dilution before you compare offers.
The instrument changes too. Early stage is common stock options, later stage moves to RSUs, and the risk profile of the two is not comparable.
4. Ability to bring team
Rarely written into the offer, frequently priced into it. A CRO who can bring two proven enterprise AEs and a sales leader is worth more than one who cannot, because the hiring cost and ramp risk of those roles is real and immediate.
This cuts both ways at the negotiating table. If you are the candidate, it is leverage. If you are the board, be specific about what bringing the team means and whether anyone has actually agreed to move.
5. Whether it is truly a CRO role
The most common source of a bad offer on both sides.
A CRO owns revenue: sales, and usually customer success, and often marketing. A VP of Sales owns sales. If marketing and CS report elsewhere, the role is a VP of Sales with a CRO title, and pricing it as a CRO is how a board overpays for scope that does not exist.
Three questions settle it. Who does marketing report to? Who owns net revenue retention? Does this role sit on the executive team and present to the board directly? If the answer to all three is not the CRO, it is a VP Sales role.
The traps, on both sides
For candidates. An inflated title with VP scope caps your next move, because your next employer will price the scope, not the title. A large equity grant at a high valuation can be worth less than a smaller grant at a lower one. And an OTE built on a number nobody in the company has hit is not compensation, it is a forecast.
For boards and CEOs. Paying CRO rates for VP scope buys resentment at the first comp review. Hiring a first-time CRO at Series C to save 20 percent usually costs more than it saves. And a CRO whose variable pay depends entirely on a number set before they arrived will spend their first quarter renegotiating it rather than selling.
What to benchmark against
Public company data comes from proxy statements and comp research firms such as Compensia and Radford. Private company data is thinner and more self-reported, which is why the spread is wider. Cross-check any single source: the range across reputable 2026 datasets for the same role and stage routinely spans $100K.
Related: the first 90 days as a new CRO, 47 sales job titles with salary bands, and how to set up a CRO advisory programme.
Related reading: The CRO's Guide to Go-to-Network: An Executive Problem
Frequently asked questions
What does a CRO earn in 2026?
Base clusters at $231K to $302K across all stages, but that average is misleading. Series A runs $200K to $250K base, pre-IPO $300K to $380K, and public company CROs $350K to $450K with annual RSU grants of $400K to $1.2M.
How much equity does a CRO get?
Roughly 0.75 to 1.5 percent at Series A, falling to 0.5 to 1.0 percent at Series B, 0.25 to 0.6 percent at Series C, and 0.10 to 0.3 percent pre-IPO, usually as RSUs. Dilution matters: each round dilutes existing holders by 10 to 25 percent, so 1.5 percent at Series A can be nearer 0.8 percent by Series C.
What is the difference between a CRO and a VP of Sales?
A CRO owns revenue, meaning sales plus usually customer success and often marketing. A VP of Sales owns sales. If marketing and CS report elsewhere, the role is a VP of Sales with a CRO title. Three questions settle it: who does marketing report to, who owns net revenue retention, and does the role present to the board.
How much more does a CRO earn than a VP of Sales?
The premium runs 20 to 35 percent in base and wider in OTE, because pay mix at C-level is typically 70/30 against 60/40 for a VP.
What is the most common mistake in a CRO offer?
Pricing an inflated title. Paying CRO rates for VP scope creates resentment at the first comp review, and accepting a CRO title without CRO scope caps the candidate's next move, because the next employer prices the scope rather than the title.
